Direxion Pharma & Medical Bull 3X

Merck's Winrevair Must Show Walking Distance Improvements to Build Confidence

Traders Pessimistic on Merck Stock, Abnormal Options Trading Occurs

Modern Wealth Management Increases Holdings in Merck

Merck CEO Garijo Reiterates Importance of Chinese Market and Discusses Collaboration Opportunities

Elo Mutual Increases Holdings in Merck

Viatris Releases Financial Projections for 2025 and 2026

Merck Announces Positive Results for KEYTRUDA and WELIREG Combination Therapy in Phase 3 Trial

Definium Therapeutics Expected to Obtain Major Drug Clinical Trial Results in 2026

Merck Reduces Staff at US HPV Vaccine Plant

FactSet: VTRS-US EPS Forecast Revised Down to $2.46 in 2026

Merck's New CMV Inhibitor Letermovir Approved by China's NMPA

Edgewise Therapeutics released FY2025 Q4 earnings on February 26 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4735 (forecast USD -0.4376)

Edgewise Therapeutics released FY2025 annual earnings on February 26 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.6301 (forecast USD -1.5955)

Definium Therapeutics released FY2025 earnings on February 26 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -2.0599 (forecast USD -1.9807)

Definium Therapeutics released FY2025 Q4 earnings on February 26 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5001 (forecast USD -0.4638)

Viatris released FY2025 Q4 earnings on February 26 During-Market (EST), actual revenue USD 3.704 B (forecast USD 3.526 B), actual EPS USD -0.295 (forecast USD -0.0316)

Viatris Reports Q4 Revenue Growth Exceeding Analysts' Expectations and Outlines 2026 Revenue Targets

RBC Capital Rates Merck 'Outperform'

Merck Animal Health Receives FDA Approval for NUMELVI

Merck Announces Phase 3 Clinical Trial Results for DOR/ISL and Plans to Submit New Drug Application

bioAffinity Tech

iSpecimen

T-REX 2X Long UPXI Daily Target ETF

Functional Brands

Firefly Neuroscience

Silvaco

eLong Power

Upexi

Polaryx Therapeutics

Shimmick

DAWN

INCY

IBBQ

PILL

ARKG

SBIO

This week's biotech news highlights significant FDA and EU approvals, including Bristol Myers Squibb's Sotyktu for psoriatic arthritis and Incyte's Zynyz for anal cancer. AstraZeneca's Koselugo for NF1 and Johnson & Johnson's AKEEGA for BRCA-mutated prostate cancer also received approvals. Ipsen withdrew Tazverik due to safety concerns. Additionally, Servier acquired Day One Biopharmaceuticals for $2.5 billion, and NEXGEL signed an agreement with Celularity to acquire regenerative biomaterial products, potentially tripling its revenue.

rttnews

Johnson & Johnson

Day One Biopharmaceuticals

Incyte

AstraZeneca

Bristol Myers Squibb

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

SPDR S&P Health Equip

VanEck Biotech ETF

iShares US Pharma

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

VG Health

Weekly Buzz: BMY Wins FDA Nod; EU Okays JNJ's AKEEGA; IPSEY Withdraws Tazverik, DAWN Acquired

ABBV

Eli Lilly & Co. (LLY) shares fell 2.26% to $977.25 on Thursday, marking the third consecutive day of losses. The stock is now 13.82% below its 52-week high of $1,133.95. In comparison, competitors like Johnson & Johnson (JNJ), Pfizer Inc. (PFE), and AbbVie Inc. (ABBV) also experienced declines, but to a lesser extent. The overall market was down, with the S&P 500 Index falling 1.52% and the Dow Jones Industrial Average down 1.56%. Trading volume was below average at 2.3 million shares.

- Shares of Eli Lilly & Co. (LLY) decreased by 2.26% to $977.25 in a poor trading session, with the S&P 500 falling 1.52% and the Dow Jones down 1.56%.  
- This marked the stock's third consecutive day of losses, and it closed 13.82% below its 52-week high of $1,133.95.  
- Eli Lilly underperformed relative to competitors like Johnson & Johnson, Pfizer, and AbbVie, all of which also experienced declines.

Dow Jones

Abbvie

Eli Lilly

Pfizer

Direxion Daily LLY Bull 2X Shares

Defiance Daily Target 2X Long LLY ETF

Eli Lilly & Co. Stock Underperforms Thursday When Compared To Competitors

- A trial comparing blood thinners Eliquis and Xarelto found that Eliquis has a significantly lower risk of dangerous bleeding in patients with blood clots.  
- The study involved 2,760 participants and indicated no significant difference in the risk of recurrent blood clots between the two drugs.  
- Additionally, changes in the aging gut were linked to cognitive decline in mice, suggesting potential for new treatments targeting gut-brain communication.

Reuters

ProShares Ultra Health Care ETF

iShares Biotechnology ETF

Bayer

iShares US Medical Devices

Health Rounds: Eliquis proves safer than Xarelto for patients with deep blood clots

In Thursday's intraday session, several health care stocks experienced significant movements. Notable gainers included Bristol-Myers Squibb (up 34.2% to $0.14), Codexis (up 33.85% to $1.7), and Agape ATP (up 23.5% to $5.15). Conversely, Incannex Healthcare saw a decline of 38.0% to $3.7, while Acurx Pharmaceuticals fell 24.38% to $4.56. Other notable losers included Rapid Micro Biosystems (down 21.58% to $3.44) and Polaryx Therapeutics (down 20.49% to $4.58).

benzinga_article

Codexi

Acurx Pharmaceuticals

Agape ATP

Rapid Micro Biosystems

Incannex Healthcare

12 Health Care Stocks Moving In Thursday's Intraday Session

Century Therapeutics

Century Therapeutics 2025 net loss narrows beating estimates

LABD

BioNTech co-founders Uğur Şahin and Özlem Türeci will step down to launch a new mRNA-focused venture as the company reported a 57% rise in net losses for 2025. Their departure marks a significant change for BioNTech, which saw its share price peak during the Covid-19 pandemic. The company is now targeting oncology to improve its financial performance, with ongoing Phase II and III programs. Analysts express mixed feelings about the leadership change, but note the potential of BioNTech's pipeline and partnerships, including a significant collaboration with Bristol Myers Squibb.

Pharmaceutical Technology

Direxion S&P Biotech Bear 3X

BioNTech SE

BioNTech co-founders step down to launch new mRNA venture

Richard Bernstein Advisors LLC has reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 60.9% in Q3, now holding 26,104 shares valued at $1.18 million. Other institutional investors have also adjusted their positions, with significant increases and new stakes. Bristol Myers Squibb's stock opened at $60.11, with a market cap of $122.41 billion. The company reported Q4 earnings of $1.26 per share, missing estimates, and announced a quarterly dividend of $0.63 per share, yielding 4.2%. Positive developments in clinical trials may enhance future revenue potential.

Market Beat

Richard Bernstein Advisors LLC Lowers Position in Bristol Myers Squibb Company $BMY

APVO

Aptevo Therapeutics shares are trading lower after the company announced new interim data for mipletamig in combination with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients who are either elderly or unfit for intensive chemotherapy.

Aptevo Therap

Bristol Myers Squibb announced that its blood cancer treatment candidate, oral mezigdomide, showed positive results in a late-stage trial. The drug, when combined with carfilzomib and dexamethasone, significantly improved progression-free survival in patients with relapsed or refractory multiple myeloma compared to existing treatments. The company's chief medical officer expressed excitement about the results, emphasizing the potential for effective oral treatment options for challenging blood cancers.

MorningStar

Bristol Myers Squibb Says Blood-Cancer Treatment Performed Well in Late-Stage Trial

Bristol Myers Squibb (BMY) announced positive interim Phase 3 results from the SUCCESSOR-2 study, showing that oral mezigdomide combined with carfilzomib and dexamethasone significantly improves progression-free survival in patients with relapsed or refractory multiple myeloma compared to carfilzomib and dexamethasone alone. The safety profile aligns with existing data on mezigdomide. The study continues to monitor patient survival and safety outcomes.

Bristol Myers Squibb Announces Positive Phase 3 Results For Mezigdomide In Multiple Myeloma

Bristol's cancer drug meets main goal in late-stage trial

Bristol Myers Squibb (BMS) has received FDA approval for Sotyktu (deucravacitinib), an oral selective TYK2 inhibitor, to treat adults with active psoriatic arthritis (PsA). This is the first TYK2 inhibitor approved for this indication. The approval is based on Phase III studies showing significant improvements in disease activity. Common side effects include acne and upper respiratory infections. Sotyktu was previously approved for moderate-to-severe plaque psoriasis. BMS emphasizes its role in managing psoriatic disease symptoms and plans further development in other conditions.

BMS gains FDA approval for Sotyktu in psoriatic arthritis treatment

Bristol Myers Squibb's stock rose over 13% in February due to positive developments despite price cuts to its top drug, Eliquis. The company reported a modest 1% revenue growth to $12.5 billion for Q4 2025, but net income fell nearly 24%. The growth portfolio, led by cancer drug Opdivo, saw a 16% increase, contrasting with a 15% decline in legacy drug revenue. Management forecasts 2026 revenue between $46 billion and $47.5 billion, exceeding analyst expectations. The FDA accepted a new drug application for iberdomide, indicating promising future growth.

nasdaq

Why Bristol Myers Squibb Stock Crushed it in February

Bristol Myers Squibb has received FDA approval for its oral drug Sotyktu to treat adults with active psoriatic arthritis, expanding its immunology portfolio. The approval follows positive results from Phase 3 trials, showing significant disease control compared to placebo. Despite a slight after-hours stock dip, the company emphasizes Sotyktu's role in managing symptoms of psoriatic disease. The drug's safety profile is similar to previous studies, with common side effects including respiratory infections and mouth ulcers. This approval builds on its initial 2022 clearance for moderate-to-severe plaque psoriasis.

Bristol-Myers Squibb Company

Bristol Myers Wins FDA Approval for Sotyktu for Psoriatic Arthritis

Bristol Myers Squibb has received FDA approval for Sotyktu® (deucravacitinib) as a treatment for adults with active psoriatic arthritis. This oral TYK2 inhibitor demonstrated significant efficacy in clinical trials, achieving higher ACR20 response rates compared to placebo. The approval highlights Sotyktu's role in managing both skin and joint symptoms of psoriatic disease. The drug is also noted for its safety profile, with common adverse reactions including upper respiratory infections and increased blood creatine phosphokinase. This marks a significant advancement in treatment options for psoriatic arthritis patients.

StockTitan

U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis | BMY Stock News

Direxion Pharma & Medical Bull 3X(PILL.US)

Weekly Buzz: BMY Wins FDA Nod; EU Okays JNJ's AKEEGA; IPSEY Withdraws Tazverik, DAWN Acquired

Eli Lilly & Co. Stock Underperforms Thursday When Compared To Competitors

Health Rounds: Eliquis proves safer than Xarelto for patients with deep blood clots

12 Health Care Stocks Moving In Thursday's Intraday Session

Century Therapeutics 2025 net loss narrows beating estimates